DaVita HealthCare Partners Inc
$ 203.83
2.66%
11 Jun - close price
- Market Cap 13,082,829,000 USD
- Current Price $ 203.83
- High / Low $ 205.42 / 198.37
- Stock P/E 19.66
- Book Value -11.41
- EPS 10.37
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.81 %
- 52 Week High 205.39
- 52 Week Low 101.00
About
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Analyst Target Price
$193.71
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-02 | 2025-10-29 | 2025-08-05 | 2025-05-12 | 2025-02-13 | 2024-10-29 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-07 | 2023-08-03 |
| Reported EPS | 2.87 | 3.4 | 2.51 | 2.95 | 2 | 2.24 | 2.59 | 2.59 | 2.38 | 1.87 | 2.85 | 2.08 |
| Estimated EPS | 2.33 | 3.19 | 3.17 | 2.75 | 2.02 | 2.13 | 2.72 | 2.63 | 1.92 | 1.66 | 2.04 | 1.74 |
| Surprise | 0.54 | 0.21 | -0.66 | 0.2 | -0.02 | 0.11 | -0.13 | -0.04 | 0.46 | 0.21 | 0.81 | 0.34 |
| Surprise Percentage | 23.176% | 6.5831% | -20.8202% | 7.2727% | -0.9901% | 5.1643% | -4.7794% | -1.5209% | 23.9583% | 12.6506% | 39.7059% | 19.5402% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 3.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVA
2026-06-12 07:39:31
This article examines DaVita Inc.'s valuation, highlighting its position as a key US dialysis provider. It discusses how DaVita's business model, which includes a network-driven approach to kidney care, influences its valuation profile, with a focus on free cash flow generation and the role of debt. The analysis also covers how interest rates, macroeconomic conditions, and the regulatory environment for healthcare in the US impact the company's financial outlook and stock valuation.
2026-06-11 22:10:49
This article provides a detailed list of the holdings for the Amundi USD High Yield Corporate Bond ESG Dist- Distribution ETF (USHY) on Euronext as of June 9, 2026. It includes data on the symbol, weight percentage, number of shares, and market value for each holding. The top holdings include a bond from 1261229 B.C. Ltd., Nexstar Media Inc., and Centene Corporation.
2026-06-11 22:07:48
DaVita HealthCare (DVA) recently closed at $203.83, surpassing the S&P 500's daily gain and showing a 0.22% increase over the last month. Analysts anticipate solid growth for DaVita, with earnings projected to rise by 35.93% year-over-year and revenue by 4.53% in the upcoming report. The stock currently holds a Zacks Rank of #1 (Strong Buy) and trades at a discount compared to its industry average valuation, indicating potential for continued strong performance.
2026-06-11 21:37:26
DaVita HealthCare (DVA) recently outperformed the S&P 500 and Dow, closing with a +2.66% gain in its latest trading session. The company is projected to report significant year-over-year growth in earnings and revenue for its upcoming release and the full year. DaVita currently holds a Zacks Rank of #1 (Strong Buy) and exhibits attractive valuation metrics compared to its industry peers.
2026-06-11 17:14:00
DaVita Inc. (DVA) saw its stock rise by 2.66% to $203.83 on Thursday, outperforming the broader market which also experienced significant gains. This marks the third consecutive day of increases for the stock. The S&P 500 Index rose 1.75% and the Dow Jones Industrial Average gained 1.86% on the same trading day.
2026-06-10 16:37:26
DaVita (DVA) is seeing stock gains due to its focus on integrated kidney care and progress in the Comprehensive Kidney Care Contracting (CKCC) program. The company delivered over 7 million dialysis treatments and expanded its Integrated Kidney Care platform to cover 62,600 patients in risk-based care arrangements in Q1 2026. DaVita also reported significant year-over-year improvements in the CKCC program and is investing in technology like its AI-enabled ScheduleHub tool, while its shares have gained 74.4% year to date and carry a Zacks Rank #2 (Buy).
